Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The approved Pfizer and Moderna mRNA vaccines are well known to induce serum antibody responses to the SARS-CoV-2 Spike (S)-protein. However, their abilities to elicit mucosal immune responses have not been reported. Saliva antibodies represent mucosal responses that may be relevant to how mRNA vaccines prevent oral and nasal SARS-CoV-2 transmission. Here, we describe the outcome of a cross-sectional study on a healthcare worker cohort (WELCOME-NYPH), in which we assessed whether IgM, IgG, and IgA antibodies to the S-protein and its receptor-binding domain (RBD) were present in serum and saliva samples. Anti-S-protein IgG was detected in 14/31 and 66/66 of saliva samples from uninfected participants after vaccine doses-1 and -2, respectively. IgA antibodies to the S-protein were present in 40/66 saliva samples after dose 2. Anti-S-protein IgG was present in every serum sample from recipients of 2 vaccine doses. Vaccine-induced antibodies against the RBD were also frequently present in saliva and sera. These findings may help our understanding of whether and how vaccines may impede SARS-CoV-2 transmission, including to oral cavity target cells.
Article activity feed
-
-
SciScore for 10.1101/2021.03.11.434841: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The WCM Institutional Review Board approved the study on 6.3.2020 with the protocol number 20-04021831 and title WELCOME trial (Weill Cornell Medicine Employees) with Dr. Silvia C. Formenti MD as the Principal Investigator. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources ELISA procedures: The assay used to quantify S-protein and anti-RBD antibodies was modified from what was described previously (15). anti-RBDsuggested: NoneBound antibodies were detected using goat anti-human horse radish peroxidase (HRP)-conjugated antibodies: anti-IgA from … SciScore for 10.1101/2021.03.11.434841: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The WCM Institutional Review Board approved the study on 6.3.2020 with the protocol number 20-04021831 and title WELCOME trial (Weill Cornell Medicine Employees) with Dr. Silvia C. Formenti MD as the Principal Investigator. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources ELISA procedures: The assay used to quantify S-protein and anti-RBD antibodies was modified from what was described previously (15). anti-RBDsuggested: NoneBound antibodies were detected using goat anti-human horse radish peroxidase (HRP)-conjugated antibodies: anti-IgA from Southern Biotech (2050-05) anti-human horsesuggested: Noneanti-IgAsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
